Comparing Medications for Adults With Type 2 Diabetes
Details of the Lipid Intermediate Outcomes: Monotherapy versus Two-Drug Combination Therapy
The addition of rosiglitazone to metformin increased LDL and HDL but also increased TG when compared to metformin monotherapy. The addition of DPP-4 inhibitors to metformin did not have an effect on HDL in comparison with metformin monotherapy.
The combination of metformin and rosiglitazone increased LDL compared to metformin monotherapy (pooled between-group difference of 14.5 mg/dL, 95 percent CI, 13.3 mg/dL to 15.7 mg/dL), with high strength of evidence.
The combination of rosiglitazone and metformin increased HDL relative to metformin monotherapy (pooled between-group difference of 2.8 mg/dL, 95 percent CI, 2.2 mg/dL to 3.5 mg/dL), with high strength of evidence. The combination of metformin and DPP-4 inhibitors did not affect HDL relative to metformin monotherapy. The pooled between-group difference in HDL for metformin compared to the combination of metformin and saxagliptin was 0.5 mg/dL (95 percent CI, -1.5 mg/dL to 2.5 mg/dL) with moderate strength of evidence. The combination of metformin plus pioglitazone was favored over metformin monotherapy with a low strength of evidence.
Metformin monotherapy decreased TG compared to the combination of metformin and rosiglitazone (pooled between-group difference -14.5 mg/dL, 95 percent CI, -15.7 mg/dL to -13.3 mg/dL), with high strength of evidence.
- Bennett WL, Wilson LM, Bolen S, et al. Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update. Comparative Effectiveness Review No. 27. (Prepared by Johns Hopkins University Evidence-based Practice Center under Contract No. 290-02-0018.) AHRQ Publication No. 11-EHC038-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2011. Available at: http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=644.
Your slide tray is being processed.